Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Vaccinia × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 203 Carcinoma, Renal Cell 75 Liver Neoplasms 62 Neoplasms 47 Leukemia, Myeloid, Acute 36 Neoplasm Metastasis 30 Carcinoma, Non-Small-Cell Lung 28 Breast Neoplasms 28 Melanoma 23 Kidney Neoplasms 21 Pancreatic Neoplasms 16 Sarcoma 14 Prostatic Neoplasms 13 Lung Neoplasms 13 Brain Neoplasms 12 Thyroid Neoplasms 11 Recurrence 11 Glioblastoma 10 Colorectal Neoplasms 10 Carcinoma 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Myelodysplastic Syndromes 8 Multiple Myeloma 8 Urinary Bladder Neoplasms 7 Unspecified Adult Solid Tumor, Protocol Specific 6 Stomach Neoplasms 6 Rectal Neoplasms 6 Ovarian Neoplasms 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Leukemia 6

Interventions

pembrolizumab 2 Docetaxel 2 Cisplatin 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 taxane 1 liposomal doxorubicin 1 durvalumab 1 cemiplimab 1 atezolizumab 1 Sorafenib 1 Pemetrexed 1 Paclitaxel 1 Nivolumab 1 Irinotecan 1 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Drug Therapy 1 Biosimilar Pharmaceuticals 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02562755 2020-12-16

PHOCUS

SillaJen, Inc.

Phase 3 Completed

459 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡